Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

76.73EUR
23 Aug 2019
Change (% chg)

€-0.29 (-0.38%)
Prev Close
€77.02
Open
€76.92
Day's High
€77.73
Day's Low
€76.52
Volume
1,823,197
Avg. Vol
2,421,830
52-wk High
€80.44
52-wk Low
€71.74

Select another date:

Thu, Aug 15 2019

Sanofi beats bid to exclude expert ‘Trojan horse’ testimony on Taxotere risk

A federal judge has rejected a bid by patients who allege Sanofi SA's cancer treatment Taxotere caused their permanent hair loss to prevent the drugmaker from presenting expert testimony based on an ex-employee's new analysis that showed minimal such side effects.

Sanofi scores double win in Federal Circuit on Jevtana patents

A federal appeals court on Wednesday delivered a double dose of good news to Sanofi-Aventis U.S., affirming the validity of its first patent on the prostate-cancer drug Jevtana and overturning a ruling against a later patent on a method of administering it.

IN BRIEF: 10th Circuit tosses lawsuit over Clomid birth defect risk warnings

A federal appeals court has upheld the dismissal of a Utah woman's lawsuit accusing Sanofi SA of failing to warn about the risks its infertility drug Clomid posed to fetuses when taken during pregnancy.

EU approves Sanofi, Regeneron's Dupixent for adolescent eczema cases

PARIS The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won regulatory approval in Europe for moderate-to-severe cases of eczema in adolescents, the companies said.

UPDATE 1-EU approves Sanofi, Regeneron's Dupixent for adolescent eczema cases

PARIS, Aug 6 The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won regulatory approval in Europe for moderate-to-severe cases of eczema in adolescents, the companies said.

EU regulators approve Sanofi, Regeneron's Dupixent for adolescent cases

PARIS, Aug 6 The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won approval in Europe for adolescents with moderate-to-severe atopic dermatitis, the companies said on Tuesday.

Sanofi raises outlook after strong second quarter

PARIS Sanofi has raised its 2019 outlook on the back of strong second-quarter results, which benefited from double-digit growth at the French drugmaker's vaccines and rare diseases businesses.

UPDATE 2-Sanofi raises outlook after strong second quarter

PARIS, July 29 Sanofi has raised its 2019 outlook on the back of strong second-quarter results, which benefited from double-digit growth at the French drugmaker's vaccines and rare diseases businesses.

Drugmaker Sanofi raises outlook after strong Q2 numbers

PARIS, July 29 Sanofi raised its 2019 outlook on the back of second-quarter results lifted by double digit growth at its vaccines and rare diseases businesses.

UPDATE 1-Sanofi ends partnership with Lexicon to develop add-on pill for diabetes

July 26 French drugmaker Sanofi SA said on Friday it had terminated its partnership with Lexicon Pharmaceuticals Inc to develop a drug for use with insulin in patients with type 1 and type 2 diabetes.

Select another date: